Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

Omidenepag isopropyl (OMDI) is an intraocular pressure (IOP)-lowering drug used to treat glaucoma. The active form of OMDI, omidenepag (OMD), lowers elevated IOP, the main risk factor for glaucoma, by increasing the aqueous humor outflow; however, a detailed understanding of this mechanism is lacking. To clarify the IOP-lowering mechanism of OMDI, the effects of OMD on the mRNA expression of the extracellular matrix, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) were evaluated in human trabecular meshwork cells. Under 2D culture conditions, the mRNA expression of FN1, COL1A1, COL1A2, COL12A1, and COL13A1 decreased in a concentration-dependent manner after 6 or 24 h treatment with 10 nM, 100 nM, and 1 μM OMD, while that of COL18A1 decreased after 6 h treatment with 1 μM OMD. Significant changes in expression were observed for many MMP and TIMP genes. Under 3D culture conditions, the extracellular matrix-related genes COL12A1 and COL13A1 were downregulated by OMD treatment at all three concentrations. Under both 2D and 3D culture conditions, COL12A1 and COL13A1 were downregulated following OMD treatment. Reduction in the extracellular matrix contributes to the decrease in outflow resistance, suggesting that the downregulation of the two related genes may be one of the factors influencing the IOP-lowering effect of OMDI. Our findings provide insights for the use of OMDI in clinical practice.

[1]  L. Delort,et al.  3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages , 2021, International Journal of Molecular Sciences.

[2]  M. Aihara,et al.  Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm’s canal endothelial cells and ciliary muscle contraction , 2021, Scientific Reports.

[3]  S. Woo,et al.  Tonsil-derived mesenchymal stem cells enhance allogeneic bone marrow engraftment via collagen IV degradation , 2021, Stem Cell Research & Therapy.

[4]  M. Fuwa,et al.  Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. , 2021, Journal of Ocular Pharmacology and Therapeutics.

[5]  J. Vranka,et al.  Normal and glaucomatous outflow regulation , 2020, Progress in Retinal and Eye Research.

[6]  M. Kageyama,et al.  Novel use of a chemically modified siRNA for robust and sustainable in vivo gene silencing in the retina , 2020, Scientific Reports.

[7]  Hao Sun,et al.  Osthole Reduces Mouse IOP Associated With Ameliorating Extracellular Matrix Expression of Trabecular Meshwork Cell , 2020, Investigative ophthalmology & visual science.

[8]  M. Aihara,et al.  Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study , 2020, Japanese Journal of Ophthalmology.

[9]  M. Aihara,et al.  Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study. , 2020, American journal of ophthalmology.

[10]  R. Maddala,et al.  Global Phosphotyrosinylated Protein Profile of Cell-Matrix Adhesion Complexes of Trabecular Meshwork Cells. , 2020, American journal of physiology. Cell physiology.

[11]  Naveed B K Shams,et al.  The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  R. Weinreb,et al.  Matrix Metalloproteinases and Glaucoma Treatment , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[13]  Yong Teng,et al.  Is It Time to Start Transitioning From 2D to 3D Cell Culture? , 2020, Frontiers in Molecular Biosciences.

[14]  R. Puga,et al.  Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. , 2020, Materials science & engineering. C, Materials for biological applications.

[15]  M. Kageyama,et al.  Rotenone-induced inner retinal degeneration via presynaptic activation of voltage-dependent sodium and L-type calcium channels in rats , 2020, Scientific Reports.

[16]  Y. Sugimoto,et al.  Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[17]  M. Filla,et al.  Role of Fibronectin in Primary Open Angle Glaucoma , 2019, Cells.

[18]  C. Traverso,et al.  2D- and 3D-cultures of human trabecular meshwork cells: A preliminary assessment of an in vitro model for glaucoma study , 2019, PloS one.

[19]  M. Aihara,et al.  Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension , 2019, Journal of glaucoma.

[20]  M. Matsusaki,et al.  Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness. , 2019, Biomaterials.

[21]  M. Fuwa,et al.  Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. , 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[22]  Naveed B K Shams,et al.  Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. , 2018, Journal of medicinal chemistry.

[23]  C. R. Ethier,et al.  Consensus recommendations for trabecular meshwork cell isolation, characterization and culture. , 2018, Experimental eye research.

[24]  Naveed B K Shams,et al.  Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. , 2018, Investigative ophthalmology & visual science.

[25]  R. Ritch,et al.  Glaucoma , 2017, The Lancet.

[26]  Jie J. Zheng,et al.  Small‐molecule inhibition of Wnt signaling abrogates dexamethasone‐induced phenotype of primary human trabecular meshwork cells , 2017, Experimental cell research.

[27]  London,et al.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. , 2017, The British journal of ophthalmology.

[28]  S. Mansberger,et al.  Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern(®) Guidelines. , 2016, Ophthalmology.

[29]  J. Vranka,et al.  Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. , 2015, Experimental eye research.

[30]  H. Tanihara,et al.  p38 MAP Kinase Inhibitor Suppresses Transforming Growth Factor-β2–Induced Type 1 Collagen Production in Trabecular Meshwork Cells , 2015, PloS one.

[31]  C. O'brien,et al.  The role of matricellular proteins in glaucoma. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[32]  Apurva R. Patel,et al.  AlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies , 2013, PloS one.

[33]  A. Soza,et al.  Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling , 2007, PloS one.

[34]  H. Quigley.  Glaucoma , 2011, The Lancet.

[35]  I. Grierson,et al.  Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. , 2009, Experimental eye research.

[36]  S. Miglior,et al.  Risk factors for glaucoma onset and progression. , 2008, Survey of ophthalmology.

[37]  A. Alm,et al.  Side effects associated with prostaglandin analog therapy. , 2008, Survey of ophthalmology.

[38]  T. Acott,et al.  Extracellular matrix in the trabecular meshwork. , 2008, Experimental eye research.

[39]  T. Noakes,et al.  The COL12A1 and COL14A1 genes and Achilles tendon injuries. , 2008, International journal of sports medicine.

[40]  K. Arai,et al.  Mechanical strain increases expression of type XII collagen in murine osteoblastic MC3T3-E1 cells. , 2008, Cell structure and function.

[41]  Maria Bokhari,et al.  Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge , 2007, Journal of anatomy.

[42]  R. Weinreb.  Glaucoma neuroprotection: What is it? Why is it needed? , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[43]  T. Acott,et al.  Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. , 2007, Investigative ophthalmology & visual science.

[44]  G. Holló.  The side effects of the prostaglandin analogues , 2007, Expert opinion on drug safety.

[45]  S. Nilsson,et al.  The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. , 2006, Investigative ophthalmology & visual science.

[46]  Mark Johnson,et al.  'What controls aqueous humour outflow resistance?'. , 2006, Experimental eye research.

[47]  H. Quigley,et al.  The number of people with glaucoma worldwide in 2010 and 2020 , 2006, British Journal of Ophthalmology.

[48]  I. Pang,et al.  TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. , 2006, Investigative ophthalmology & visual science.

[49]  JONG BIN Kim,et al.  Three-dimensional tissue culture models in cancer biology. , 2005, Seminars in cancer biology.

[50]  H. Thieme,et al.  Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. , 2005, Experimental eye research.

[51]  C. May,et al.  Localization of Collagen XVIII and Endostatin in the Human Eye , 2005, Current eye research.

[52]  P. Kaufman,et al.  Effects of prostaglandins on the aqueous humor outflow pathways. , 2002, Survey of ophthalmology.

[53]  T. Pihlajaniemi,et al.  Type XIII collagen: a novel cell adhesion component present in a range of cell-matrix adhesions and in the intercalated discs between cardiac muscle cells. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[54]  M. Chiquet,et al.  Rapid and reciprocal regulation of tenascin-C and tenascin-Y expression by loading of skeletal muscle. , 2000, Journal of cell science.

[55]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[56]  S. Peltonen,et al.  A novel component of epidermal cell-matrix and cell-cell contacts: transmembrane protein type XIII collagen. , 1999, The Journal of investigative dermatology.

[57]  M. Chiquet,et al.  Rapid and reversible regulation of collagen XII expression by changes in tensile stress. , 1999, Experimental cell research.

[58]  Douglas R. Anderson,et al.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[59]  Douglas R. Anderson,et al.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[60]  H. Quigley.  Number of people with glaucoma worldwide. , 1996, The British journal of ophthalmology.

[61]  I. Nishimura,et al.  Temporal and Spatial Expressions of Type XII Collagen in the Remodeling Periodontal Ligament during Experimental Tooth Movement , 1995, Journal of dental research.

[62]  B. Tengroth,et al.  Collagen distribution in the lamina cribrosa and the trabecular meshwork of the human eye. , 1987, The British journal of ophthalmology.